(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers… Read on
(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment… Read on
(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage… Read on
(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery… Read on
(November 16, 2018) JAMA Internal Medicine recently published an eleven year study of over 72,000 women that found having a simple ovarian cyst does not increase one’s risk of ovarian cancer… Read on
(November 13, 2018) The International Journal of Cancer recently published a study that explored the use of statins, which reduces one’s lipids, and their effect on ovarian cancer risk… Read on
(October 25, 2018) Through a series of surveys, interviews, and literature reviews the World Ovarian Cancer Coalition produced a report that detailed their findings and recommendations… Read on
(October 23, 2018) Olaparib, or Lynparza, was shown to increase progression-free survival (PFS) by almost three years in an ongoing trial known as SOLO-1… Read on
(October 22, 2018) A team at the University of Illinois at Chicago, including OCRA grantee Matthew Dean, PhD, recently discovered the role that cancer cells have on their immediate environment. The research was funded in part by OCRA… Read on
(October 19, 2018) A retroactive study using SEER, or Surveillance, Epidemiology, and End Results, looked at the trends in ovarian cancer from 1983 to 2012. In almost 3 decades, the incidence of ovarian cancer per 100,000 fell from 13.7 to 10… Read on
